Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

Masaki Shiota, Akira Yokomizo, Masatoshi Eto

Research output: Contribution to journalShort survey

16 Citations (Scopus)

Abstract

Historically, androgen-deprivation therapy (ADT) was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer (CRPC), there are a few life-prolonging drugs, including taxanes, such as docetaxel and cabazitaxel, as well as novel androgen receptor-targeting agents, such as abiraterone acetate and enzalutamide, which have been proved in clinical trials. However, the prognosis of men with CRPC is still poor. The duration from initiation of ADT to CRPC has not improved in recent decades because no novel therapeutic options have emerged. However, recently, up-front docetaxel chemotherapy has been shown to prolong progression-free as well as overall survival in men with metastatic hormone-naïve prostate cancer. This offers a new way to expand the role of chemotherapy for hormone-naïve prostate cancer. In this review, we summarize the proof-of-concept as well as the current status of taxane chemotherapy for hormone-naïve prostate cancer, focusing on phase 3 clinical trials investigating oncological outcome, and discuss the future direction in this field.

Original languageEnglish
Article number304
JournalFrontiers in Oncology
Volume5
Issue numberJAN
DOIs
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy'. Together they form a unique fingerprint.

  • Cite this